| Market Cap | 892.31Cr 768.99Cr 708.12Cr 664.86Cr 1.25TCr 84TCr 1.26TCr 8.37TCr 3.26TCr 41TCr 3.35TCr 3.28TCr 1,43200Cr | P/E Ratio 2026 * |
159x | P/E Ratio 2027 * | 34.5x |
|---|---|---|---|---|---|
| Enterprise Value | 870.97Cr 750.6Cr 691.18Cr 648.96Cr 1.22TCr 82TCr 1.23TCr 8.17TCr 3.18TCr 40TCr 3.27TCr 3.2TCr 1,39700Cr | EV / Sales 2026 * |
8.66x | EV / Sales 2027 * | 6.03x |
| Free-Float |
65.96% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Corcept Therapeutics
| 1 day | +0.16% |
| Manager | Title | Age | Since |
|---|---|---|---|
Joseph Belanoff
CEO | Chief Executive Officer | 68 | 01/01/1999 |
Atabak Mokari
DFI | Director of Finance/CFO | 49 | 01/03/2021 |
Joseph Lyon
CTO | Chief Tech/Sci/R&D Officer | 48 | 01/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Belanoff
BRD | Director/Board Member | 68 | 01/01/1999 |
James Wilson
CHM | Chairman | 82 | 01/01/1999 |
David Mahoney
BRD | Director/Board Member | 71 | 01/07/2004 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.16% | +13.02% | - | - | 892.31Cr | |
| -0.61% | -1.94% | +39.00% | +150.72% | 1,00700Cr | |
| -0.20% | -0.77% | +51.51% | +43.20% | 57TCr | |
| +0.40% | -1.31% | +16.56% | +60.47% | 39TCr | |
| -0.80% | +1.05% | +20.91% | +18.37% | 33TCr | |
| -0.43% | +2.01% | +23.20% | +32.46% | 28TCr | |
| +0.64% | -3.71% | +20.92% | +13.67% | 28TCr | |
| -1.86% | +3.05% | -45.70% | -49.24% | 20TCr | |
| -0.77% | +0.95% | +17.69% | +51.46% | 19TCr | |
| +2.36% | +1.38% | +14.80% | +61.34% | 15TCr | |
| Average | -0.17% | +0.33% | +17.65% | +42.49% | 37.62TCr | |
| Weighted average by Cap. | -0.33% | -0.03% | +26.78% | +67.42% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 100.61Cr 87Cr 80Cr 75Cr 140.74Cr 9.51TCr 142.23Cr 943.44Cr 367.54Cr 4.66TCr 377.57Cr 369.55Cr 16TCr | 140.01Cr 120.66Cr 111.11Cr 104.32Cr 195.87Cr 13TCr 197.94Cr 1.31TCr 511.49Cr 6.48TCr 525.45Cr 514.29Cr 22TCr |
| Net income | 8.57Cr 7.39Cr 6.8Cr 6.39Cr 12Cr 810.52Cr 12Cr 80Cr 31Cr 396.91Cr 32Cr 31Cr 1.38TCr | 37Cr 32Cr 29Cr 27Cr 52Cr 3.48TCr 52Cr 345.61Cr 134.64Cr 1.71TCr 138.32Cr 135.38Cr 5.91TCr |
| Net Debt | -21Cr -18Cr -17Cr -16Cr -30Cr -2.02TCr -30Cr -200.1Cr -78Cr -987.96Cr -80Cr -78Cr -3.42TCr | -47Cr -41Cr -38Cr -35Cr -66Cr -4.48TCr -67Cr -444.67Cr -173.23Cr -2.2TCr -177.96Cr -174.18Cr -7.61TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
